GlaxoSmithKline to Conduct Whole-Genome Association Studies Using Affymetrix Technology
News Oct 06, 2005
Affymetrix Inc. has announced that GlaxoSmithKline (GSK) has selected the Affymetrix GeneChip® Human Mapping 500K Array Set to find the genetic variations associated with diseases.
Under the agreement, GSK will use the arrays to perform whole-genome association studies across tens of thousands of samples.
The Affymetrix GeneChip 500K is designed to enable researchers to examine the entire genome in more detail.
Affymetrix claims that, with the array set, scientists can perform an entire association study - from conducting an initial high-resolution scan of the entire genome to identifying the specific SNPs of interest - all on one platform for less than a quarter of a cent per SNP.
The 500K is built on the same industry standard platform as its predecessors, the 10K and 100K, which have been validated in 50 publications.
"This agreement demonstrates the power of genetics in the drug discovery and development process," said Greg Yap, vice president of DNA Products at Affymetrix.
"The GeneChip Human Mapping 500K Array Set enables researchers to perform highly detailed whole-genome association studies for the first time."
"We anticipate that a better understanding of human genetic variations will dramatically accelerate research and, ultimately, help bring more effective tests and therapies to market faster."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.